Novartis Finds FREEDOM From Fingolimod Concerns In Second Phase III, Limits Dose To Play It Safe
This article was originally published in The Pink Sheet Daily
Executive Summary
FREEDOMS clinical trial show lower levels of cancer than first Phase III trial, but Novartis goes one step further by eliminating the highest dose of its oral MS therapy and thus minimizing the side effects associated with FTY720.
You may also be interested in...
Novartis Talking About Fingolimod Safety With FDA; Will Talk To Advisory Panel In June
Structure of the REMS for oral multiple sclerosis drug Gilenia likely to be discussed at committee meeting close to review deadline.
Novartis Talking About Fingolimod Safety With FDA; Will Talk To Advisory Panel In June
Structure of the REMS for oral multiple sclerosis drug Gilenia likely to be discussed at committee meeting close to review deadline.
Novartis Holds Lead In Oral MS Space With Fingolimod Filing
Novartis has gained the lead in the race to market for the first oral therapy for multiple sclerosis with the NDA submission for fingolimod, a feat made possible by FDA's refusal to file the earlier NDA for Merck Serono's oral MS candidate cladribine